Robert W. Baird Issues Pessimistic Forecast for Bright Minds Biosciences (NASDAQ:DRUG) Stock Price

Bright Minds Biosciences (NASDAQ:DRUG) had its target price cut by equities research analysts at Robert W. Baird from $126.00 to $107.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird‘s target price would indicate a potential upside of 308.40% from the stock’s previous close.

Other analysts also recently issued reports about the stock. Benchmark reiterated a “buy” rating on shares of Bright Minds Biosciences in a research report on Thursday, August 20th. Wall Street Zen cut shares of Bright Minds Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, October 3rd. HC Wainwright restated a “buy” rating and issued a $145.00 price target on shares of Bright Minds Biosciences in a research note on Wednesday, August 19th. Zacks Research cut Bright Minds Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 15th. Finally, Lifesci Capital raised Bright Minds Biosciences to a “strong-buy” rating in a report on Monday, September 28th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $126.29.

Bright Minds Biosciences Price Performance

Shares of NASDAQ DRUG opened at $26.20 on Tuesday. Bright Minds Biosciences has a 1-year low of $18.90 and a 1-year high of $123.75. The business’s fifty day moving average price is $58.16 and its two-hundred day moving average price is $73.00. The firm has a market capitalization of $254.98 million, a PE ratio of -12.60 and a beta of -5.22.

Bright Minds Biosciences (NASDAQ:DRUG) last posted its earnings results on Friday, August 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.22) by $1.05. Equities research analysts expect that Bright Minds Biosciences will post -2.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bright Minds Biosciences

Institutional investors have recently added to or reduced their stakes in the company. Engineers Gate Manager LP bought a new stake in shares of Bright Minds Biosciences in the 2nd quarter worth $380,000. Bank of New York Mellon Corp bought a new position in Bright Minds Biosciences during the second quarter valued at about $1,046,000. Seven Fleet Capital Management LP bought a new position in Bright Minds Biosciences during the first quarter valued at about $467,000. Vivo Capital LLC grew its holdings in Bright Minds Biosciences by 11.1% during the first quarter. Vivo Capital LLC now owns 557,172 shares of the company’s stock worth $40,657,000 after acquiring an additional 55,555 shares during the period. Finally, Bank of America Corp DE grew its holdings in Bright Minds Biosciences by 28.8% during the first quarter. Bank of America Corp DE now owns 19,422 shares of the company’s stock worth $1,417,000 after acquiring an additional 4,347 shares during the period. 40.52% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Bright Minds Biosciences

Here are the key news stories impacting Bright Minds Biosciences this week:

• Negative Sentiment: The FDA cited toxicity findings in mice, along with insufficient pharmacokinetic and juvenile-toxicity data, in placing the BMB-101-105 study on partial hold. Bright Minds must address the agency’s concerns before the trial can proceed fully, weakening near-term expectations for the epilepsy program. Bright Minds Biosciences Provides Update About Planned Study with BMB-101
• Negative Sentiment: The hold affects a planned randomized Phase 2 study intended to evaluate BMB-101 in developmental and epileptic encephalopathies, making the company’s lead clinical catalyst less predictable and potentially delaying future data readouts or development milestones. FDA dims Bright Minds outlook with partial hold
• Negative Sentiment: BTIG lowered its price target for DRUG to $37, signaling reduced confidence in the company’s near-term outlook following the FDA action. Although the revised target remains above the stock’s stated opening price, the cut reinforces the negative investor reaction. Bright Minds PT lowered to $37 at BTIG
• Neutral Sentiment: Levi & Korsinsky announced an investigation into potential claims on behalf of investors who suffered losses. The notice does not itself establish wrongdoing, but it adds legal and reputational uncertainty. Bright Minds Biosciences Investigation Notice
• Neutral Sentiment: Trading in DRUG was temporarily halted for news pending as the FDA-related announcement was disseminated.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc is a biotechnology company focused on developing novel treatments for neurological and psychiatric disorders. The company’s research is centered on serotonergic compounds designed to provide therapeutic benefits associated with psychedelic medicines while potentially reducing unwanted effects such as hallucinations and cardiovascular or behavioral complications.

Bright Minds’ pipeline includes BMB-101, a selective serotonin 5-HT2C receptor agonist being developed for conditions including substance use disorders.